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Concurrent
Plasmodium vivax
Malaria and
Dengue 
To the Editor: The first report of a
patient with concurrent malaria
(Plasmodium falciparum) and dengue
was recently published in this journal
(1). Herein is presumably the first
report of concurrent dengue and
malaria due to P. vivax.
A 27-year-old woman experienced
the onset of myalgia on December 11,
2003, 1 day before returning home to
California from India after a 3-month
sojourn in that country. The following
day she had chills and a low-grade
fever, and she visited an urgent care
center. A presumptive diagnosis of
influenza was made, and she was dis-
charged with antipyretic therapy. A
single malaria smear was subsequent-
ly reported to be negative for
Plasmodium.
On December 15, she sought treat-
ment at a hospital emergency depart-
ment at 3:30 A.M. with an oral temper-
ature of 39.5°C. Her leukocyte count
was 4,300 × 109/L hemoglobin level
119 g/L, and platelet count 157,000 ×
109/L. A diagnosis of probable viral
syndrome was made, and she was dis-
charged with antipyretic therapy. She
returned to the urgent care center the
following day with a temperature of
38.6°C, and a 10-day course of amox-
icillin was prescribed on discharge.
On December 18, she sought treat-
ment from an infectious disease spe-
cialist. She had an oral temperature of
39.3°C and was dehydrated, which led
to her admission to the hospital.
Results of the examination were other-
wise unremarkable.
She reported that she had lived in
the United States for the last 4 years,
after moving there from India. During
her recent trip to India, she had spent
most of the time in Surat, followed by
3 days in Mumbai. She indicated that
she had had malaria several times
while living in India. She received no
vaccinations before her trip and took
no malaria prophylaxis; she believed
she was likely immune and, in addi-
tion, she was concerned about taking
medications while breastfeeding her 6-
month-old child. The child received no
prophylaxis or other medical prepara-
tion for the trip but remained well.
Her leukocyte count was 4,500 ×
109/L with 50% polymorphonuclear
leukocytes, 18% band forms, 3%
myelocytes, and 1% metamyelocytes.
Hemoglobin level was 11.1 g/L, and
platelet count was now 98.0 × 109/L.
P. vivax was seen on blood smear, and
the patient was treated with chloro-
quine with rapid resolution of her
fever, followed by administration of
primaquine, during which course she
avoided breastfeeding. In addition,
enzyme immunoassays for dengue
virus were performed on December
19 (immunoglobulin  G [IgG]) 6.55;
IgM 4.17) and subsequently repeated
on December 31 (IgG 7.29; IgM
1.07), indicating an acute infection.
Viral isolation was not attempted.
I agree with Charrel and col-
leagues (1) that, although only 2 cases
have now been reported, concurrent
dengue and malaria is probably not a
rare event. This conclusion is support-
ed by a recent report from Pakistan
(2).
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Viruses from
Nonhuman
Primates 
To the Editor: I read with interest
the article by Jones-Engel et al. (1),
which described the frequency of
viruses infecting temple rhesus
macaques. The investigation included
the polyomavirus simian virus 40
(SV40), a pathogen recognized to
have infected millions of humans who
were vaccinated with polio vaccines
produced in cultures of rhesus mon-
key kidney cells (2,3). The authors
indicated that technologic advances
have improved the specificity of
detecting SV40 antibodies and used
an enzyme immunoassay based on
viruslike particles (VLPs) to perform
the analysis (1). However, the speci-
ficity of the SV40 enzyme immunoas-
say is problematic because studies
with serum samples from macaques
have found that antibodies are cross-
reactive with polyomaviruses JCV
and BKV (4). In addition, in monkey
sera SV40 VLPs correlated with BKV
antibodies. Similar conflicting results
have been found in human studies that
used polyomavirus VLPs assays (3).
These limitations are the result of
polyomavirus VLPs assays using
expression of the VP1 capsid protein
(4), a highly homologous gene among
JCV, BKV, and SV40 (3). In contrast,
modern molecular biology assays are
the preferred method for the analysis
of SV40 infections (2,3). In addition,
these sensitive and specific tech-
niques can provide insights into the
distribution of SV40 strains and vari-
ants (2,3). This is important because
recent data suggest that the biological
properties of SV40 strains vary in
vivo (5).
Because current evidence shows
that SV40 infections are identified in
some humans and that the virus is
associated with selected human
malignancies (2,3), prospective longi-
tudinal studies that use molecular
LETTERS
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 12, No. 11, November 2006 1803
techniques are needed to examine the
prevalence and ecology of SV40. The
Institute of Medicine recognizes that
the biologic evidence indicates that
infections with this DNA virus could
lead to cancer in humans and recom-
mends targeted biologic research of
SV40 in human populations (2).
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In response: Dr. Vilchez (1) raised
questions regarding the specificity of
the SV40 viruslike particle
(VLP)–based ELISA used to detect
SV40 infection in temple monkeys
(2). Although it is true that SV40
infection can elicit low-level, cross-
reactive antibodies that recognize
polyomavirus BKV and to a lesser
extent polyomavirus JCV VLPs and,
conversely, BKV and JCV infection
may elicit low-titer SV40 cross-reac-
tive antibodies (3), these antibodies
do not pose a problem for serologic
diagnosis of infection in natural hosts
of these polyomaviruses. Unless one
were to hypothesize that BKV and
JCV could infect macaques, SV40
VLP-reactive antibodies could not
possibly be produced by anything
other than an SV40 infection. In addi-
tion, SV40 seroreactivity in macaques
is generally very strong but cross-
reactive responses are weak (3). 
Specificity of SV40 seroreactivity
in macaques has recently been
demonstrated by competitive inhibi-
tion assays (4). SV40 reactivity was
blocked by incubation of sera with
SV40 VLPs but not significantly
reduced by incubation with BKV or
JCV VLPs. Specificity of BKV and
JCV VLP reactivity in human sera has
also been demonstrated by preabsorp-
tion with VLPs (5) and competitive
inhibition assays (4). Thus, BKV VLP
seroreactivity can be completely
inhibited by BKV VLPs but not by
JCV VLPs and vice versa. When
polyomavirus VLP ELISAs are used
to diagnosis cross-species infection,
such as SV40 infection in humans,
competitive inhibition assays are nec-
essary to verify specificity of the
response. Engels et al. (6), using
SV40 VLP serology and competitive
inhibition assays, recently reported
evidence for possible infection of zoo
workers with SV40. We agree with
Dr. Vilchez that molecular biology
assays, such as PCR, play a valuable
role in viral diagnosis. However, these
assays also have limitations in terms
of sensitivity and specificity and
therefore are best combined with the
full range of viral diagnostic tech-
niques to confirm infection. Serologic
testing is more suitable than other
assays for estimating cumulative
infection.
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